Lu et al. found that AS-IV (16, 32, and 64 μM) could reduce LPS-induced myocardial hypertrophy, and its mechanism was related to the inhibition of the CaN/NFAT-3/GATA-4 signaling pathway (Lu et al., 2014). The gene discussed is NFATC4; the disease is cardiac hypertrophy.